171 related articles for article (PubMed ID: 31622673)
1. Emerging targets for cough therapies; NK1 receptor antagonists.
Badri H; Smith JA
Pulm Pharmacol Ther; 2019 Dec; 59():101853. PubMed ID: 31622673
[TBL] [Abstract][Full Text] [Related]
2. Antitussive activity of the tachykinin NK1 receptor antagonist, CP-99994, in dogs.
Chapman RW; House A; Liu F; Celly C; Mei H; Hey JA
Eur J Pharmacol; 2004 Feb; 485(1-3):329-32. PubMed ID: 14757157
[TBL] [Abstract][Full Text] [Related]
3. Effect of the two tachykinin antagonists, SR 48968 and SR 140333, on cough induced by citric acid in the unanaesthetized guinea pig.
Girard V; Naline E; Vilain P; Emonds-Alt X; Advenier C
Eur Respir J; 1995 Jul; 8(7):1110-4. PubMed ID: 7589394
[TBL] [Abstract][Full Text] [Related]
4. Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights.
Smith JA; Harle A; Dockry R; Holt K; Russell P; Molassiotis A; Yorke J; Robinson R; Birrell MA; Belvisi MG; Blackhall F
Am J Respir Crit Care Med; 2021 Mar; 203(6):737-745. PubMed ID: 32966755
[No Abstract] [Full Text] [Related]
5. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
Coveñas R; Rodríguez FD; Robinson P; Muñoz M
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
[TBL] [Abstract][Full Text] [Related]
6. Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes.
Liu X; Zhu Y; Zheng W; Qian T; Wang H; Hou X
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1628-1634. PubMed ID: 31010320
[TBL] [Abstract][Full Text] [Related]
7. Potential therapeutic targets for neurokinin-1 receptor antagonists.
Duffy RA
Expert Opin Emerg Drugs; 2004 May; 9(1):9-21. PubMed ID: 15155133
[TBL] [Abstract][Full Text] [Related]
8. Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial.
Noronha V; Bhattacharjee A; Patil VM; Joshi A; Menon N; Shah S; Kannan S; Mukadam SA; Maske K; Ishi S; Prabhash K
Chest; 2020 Jun; 157(6):1647-1655. PubMed ID: 31958446
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis.
Rojas C; Raje M; Tsukamoto T; Slusher BS
Eur J Pharmacol; 2014 Jan; 722():26-37. PubMed ID: 24184669
[TBL] [Abstract][Full Text] [Related]
10. SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.
Anthes JC; Chapman RW; Richard C; Eckel S; Corboz M; Hey JA; Fernandez X; Greenfeder S; McLeod R; Sehring S; Rizzo C; Crawley Y; Shih NY; Piwinski J; Reichard G; Ting P; Carruthers N; Cuss FM; Billah M; Kreutner W; Egan RW
Eur J Pharmacol; 2002 Aug; 450(2):191-202. PubMed ID: 12206858
[TBL] [Abstract][Full Text] [Related]
11. A Novel Mechanism of Endoplasmic Reticulum Stress- and c-Myc-Degradation-Mediated Therapeutic Benefits of Antineurokinin-1 Receptor Drugs in Colorectal Cancer.
Shi Y; Wang X; Meng Y; Ma J; Zhang Q; Shao G; Wang L; Cheng X; Hong X; Wang Y; Yan Z; Cao Y; Kang J; Fu C
Adv Sci (Weinh); 2021 Nov; 8(21):e2101936. PubMed ID: 34605226
[TBL] [Abstract][Full Text] [Related]
12. Role of substance P and tachykinin receptor antagonists in citric acid-induced cough in pigs.
Moreaux B; Nemmar A; Vincke G; Halloy D; Beerens D; Advenier C; Gustin P
Eur J Pharmacol; 2000 Nov; 408(3):305-12. PubMed ID: 11090648
[TBL] [Abstract][Full Text] [Related]
13. Tranexamic acid induces kaolin intake stimulating a pathway involving tachykinin neurokinin 1 receptors in rats.
Kakiuchi H; Kawarai-Shimamura A; Kuwagata M; Orito K
Eur J Pharmacol; 2014 Jan; 723():1-6. PubMed ID: 24333477
[TBL] [Abstract][Full Text] [Related]
14. The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors.
Kolorz J; Demir S; Gottschlich A; Beirith I; Ilmer M; Lüthy D; Walz C; Dorostkar MM; Magg T; Hauck F; von Schweinitz D; Kobold S; Kappler R; Berger M
Curr Oncol; 2021 Dec; 29(1):94-110. PubMed ID: 35049682
[TBL] [Abstract][Full Text] [Related]
15. Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant.
Jacob D; Busciglio I; Burton D; Halawi H; Oduyebo I; Rhoten D; Ryks M; Harmsen WS; Camilleri M
Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G505-G510. PubMed ID: 28814387
[TBL] [Abstract][Full Text] [Related]
16. Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
Di Fabio R; Alvaro G; Braggio S; Carletti R; Gerrard PA; Griffante C; Marchioro C; Pozzan A; Melotto S; Poffe A; Piccoli L; Ratti E; Tranquillini E; Trower M; Spada S; Corsi M
Bioorg Med Chem; 2013 Nov; 21(21):6264-73. PubMed ID: 24075145
[TBL] [Abstract][Full Text] [Related]
17. Current and future prospects for drugs to suppress cough.
Chung KF
IDrugs; 2003 Aug; 6(8):781-6. PubMed ID: 12917774
[TBL] [Abstract][Full Text] [Related]
18. Rolapitant hydrochloride: prophylactic treatment for chemotherapy-induced nausea and vomiting.
Navari R
Drugs Today (Barc); 2016 Aug; 52(8):431-438. PubMed ID: 27722211
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor.
Watanabe Y; Asai H; Ishii T; Kiuchi S; Okamoto M; Taniguchi H; Nagasaki M; Saito A
J Pharmacol Sci; 2008 Jan; 106(1):121-7. PubMed ID: 18187929
[TBL] [Abstract][Full Text] [Related]
20. Neurokinin-1 (NK₁) receptor antagonists as possible therapeutics for psychostimulant use disorders.
Olive MF
CNS Neurol Disord Drug Targets; 2015; 14(6):700-6. PubMed ID: 26022261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
